Particularly relevant to pT217‐tau's role as an emerging fluid biomarker in AD, pT217‐tau could be seen trafficking between neurons, where it was exposed to the extracellular space, and thus accessible to CSF and blood (Figure 8C). The gene discussed is MAPT; the disease is Alzheimer disease.